Marc Wein MD, PhD, 2018 Harrington Scholar-Innovator, is an investigator in the Massachusetts General Hospital Endocrine Unit with a clinical focus on osteoporosis and metabolic bone diseases. He recently licensed the IP for novel orally-available salt inducible kinase (SIK) inhibitors, developed in large part with Harrington Discovery Institute, to Radius Health. Dr. Wein’s team, including collaborators at the Dana-Farber Cancer Institute and the Broad Institute, found that a small molecule SIK inhibitor, YKL-05-099, builds new bone by mimicking the effects of a parathyroid hormone.
This license agreement will facilitate future development of SIK inhibitors for osteoporosis and other indications. In addition to the license contract, Dr. Wein will continue to collaborate with Radius during the ‘lead optimization’ phase of his project.
“Oral bone building medications for osteoporosis remain a major unmet medical need. This is a perfect opportunity to move discoveries from the laboratory toward patients. I’m thrilled about this news, and am extremely grateful to Harrington Discovery Institute for all the support that led to this major project milestone.”
- Marc Wein, MD, PhD
"In addition to providing grant funding, Harrington Discovery Institute was able to offer invaluable guidance through our project management team. Dr. Wein's discovery has the potential to significantly improve human health and we are excited to support innovations to advance our mission."
- Jonathan S. Stamler, MD, President, Harrington Discovery Institute
Robert S. & Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation
Click here to read the full press release
Massachusetts General Hospital
2018 Harrington Scholar-Innovator